Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价皮肤试验用结核分枝杆菌抗原(D-EC)在3周岁至17周岁、66周岁至75周岁人群中的安全性和耐受性IIb期临床试验
[Translation] Phase IIb clinical trial to evaluate the safety and tolerability of Mycobacterium tuberculosis antigen (D-EC) for skin testing in people aged 3 to 17 years and 66 to 75 years
主要研究目的: (1)评价皮肤试验用结核分枝杆菌抗原(D-EC)用于人体研究的安全性和耐受性; (2)评估 D-EC 临床使用剂量的不良反应发生率与 D-EC 的关联性。 次要研究目的: (1)评价 D-EC 与 TB-PPD、IGRA 三种检测试剂在 66 周岁至 75 周岁人群胸部影像学检查正常受试者、肺结核患者中的关联性; (2) 评价 D-EC 与 IGRA 两种检测试剂在 3 周岁至 17 周岁人群健康受试者、呼吸道疾病含结核病患者中的关联性;
[Translation] Primary study objectives: (1) To evaluate the safety and tolerability of skin test Mycobacterium tuberculosis antigen (D-EC) in human studies; (2) To evaluate the correlation between the incidence of adverse reactions to the clinical dose of D-EC and D-EC. Secondary study objectives: (1) To evaluate the correlation between D-EC and three test reagents, TB-PPD and IGRA, in subjects with normal chest imaging and pulmonary tuberculosis aged 66 to 75 years; (2) To evaluate the correlation between D-EC and two test reagents, IGRA, in healthy subjects aged 3 to 17 years and patients with respiratory diseases including tuberculosis;
随机、盲法、同类制品对照探索重组结核杆菌融合蛋白(D-EC)在18~65周岁人群中皮试应用剂量的Ⅱ期临床试验
[Translation] A randomized, blinded, and similar product-controlled phase II clinical trial to explore the skin test application dose of recombinant Mycobacterium tuberculosis fusion protein (D-EC) in people aged 18 to 65 years old
(1)初步确定D-EC的阳性判定标准,为III期临床研究最终阳性判断标准确定提供依据;(2)确定III期临床使用剂量;(3)评估D-EC临床使用的安全性与剂量,及不良反应发生率与D-EC的关联性。
[Translation] (1) Preliminarily determine the positive judgment criteria for D-EC to provide a basis for determining the final positive judgment criteria for Phase III clinical studies; (2) Determine the dose used in Phase III clinical studies; (3) Evaluate the safety and dose of D-EC in clinical use, and the correlation between the incidence of adverse reactions and D-EC.
评价重组结核杆菌融合蛋白(D-EC)皮试后的安全性和耐受性I期临床研究
[Translation] Phase I clinical study to evaluate the safety and tolerability of recombinant tuberculosis fusion protein (D-EC) after skin test
试验目的是评价重组结核杆菌融合蛋白(D-EC)用于人体研究的安全性和耐受性
[Translation] The purpose of the trial is to evaluate the safety and tolerability of recombinant Mycobacterium tuberculosis fusion protein (D-EC) for human studies
100 Clinical Results associated with Kangweizhonghe (Zhongshan) Biopharmaceutical Co., Ltd.
0 Patents (Medical) associated with Kangweizhonghe (Zhongshan) Biopharmaceutical Co., Ltd.
100 Deals associated with Kangweizhonghe (Zhongshan) Biopharmaceutical Co., Ltd.
100 Translational Medicine associated with Kangweizhonghe (Zhongshan) Biopharmaceutical Co., Ltd.